Expert Opinion on Drug Discovery • July 4, 2026 • Christopher D. Verrico, Lynnette A. Averill, Cameron J Moore et al.
Ibogaine, a natural alkaloid, shows potential for treating substance use disorders, trauma, mood disorders, and suicidality, but clinical use is limited by safety concerns and regulatory barriers. Researchers are pursuing two main strategies: developing ibogaine-like compounds that keep broad effects while reducing risks, and creating selective 'bespoke' analogs targeting specific conditions like opioid use disorder, traumatic brain injury, or PTSD. The authors emphasize that the field should avoid oversimplified views that derivatives are uniformly better or interchangeable, and call for greater conceptual clarity and mechanistic humility as ibogaine-based therapies move toward regulated medical use.
Alcoholism & Drug Abuse Weekly • June 29, 2026 • Alison Knopf
The Michigan Society of Addiction Medicine opposes a bill that would redirect opioid settlement funds toward research on ibogaine, a psychedelic drug, arguing that such funds should instead be used for evidence-based treatments for opioid use disorder.
Journal of pharmaceutical and biomedical analysis • June 24, 2026 • Scot Mcintosh, Isabella Maldonado, Nickalus C Smith et al.
A sensitive UPLC-MS/MS method was developed and validated to quantify ibogaine, noribogaine, ibogamine, and oxa-noribogaine in rat brain microdialysate, measuring pharmacologically active, unbound drug in brain extracellular fluid rather than total tissue content. The method achieved lower limits of quantification of 0.78-1.56 ng/mL with a 6-minute run time, and calibration curves were linear over 0.78-75 ng/mL for ibogamine and 1.56-75 ng/mL for the other analytes. Accuracy and precision met acceptance criteria. Applied to rats (n=4), noribogaine in nucleus accumbens after 10 mg/kg intraperitoneal administration reached a peak unbound concentration of 292 ± 68 ng/mL at 50 minutes, demonstrating suitability for real-time neuropharmacokinetic profiling of iboga alkaloids.
Research Square • June 17, 2026 • Martijn Arns, Kenneth Shinozuka, Joseph Barsuglia
Ibogaine, a substance showing early promise for treating substance use disorders and PTSD in veterans, carries a risk of cardiac arrhythmia and death. A retrospective multisite study of 19,071 patients treated under safety guidelines at 11 international clinics found that all six deaths occurring within 72 hours were among patients treated for opioid use disorder (6 out of 10,382), with no deaths among 8,689 non-SUD patients. A systematic review of ibogaine-associated fatalities mirrored this pattern: 41 of 44 fatalities with known indication involved substance use disorder, predominantly opioid detoxification. The findings indicate that ibogaine-associated mortality is largely confined to opioid detoxification and rare in non-SUD indications.
Zenodo (CERN European Organization for Nuclear Research) • June 12, 2026 • Saeid Ghiasi
A system is described that maps human brain activity (EEG frequency, amplitude, and phase) to the behavior of a living slime mold (Physarum polycephalum) to create a biohybrid interface for addiction recovery. The slime mold's network growth and retraction are controlled by nutrient gradients that correspond to neural signals: higher activation in addiction-related brain regions reduces food at corresponding Physarum nodes, causing network retraction. The system is presented as a structural isomorphism—not a metaphor—between neural plasticity, Physarum tube reinforcement, and ibogaine's neurorestorative mechanisms (NMDA receptor blockade, BDNF/GDNF upregulation). The document is a defensive publication establishing prior art under patent treaties, released under CC-BY 4.0.
DELOS Desarrollo Local Sostenible • June 3, 2026 • Ana Lara Mendonça, Déborah Rezende, Gabriela Alves et al.
Ibogaine, an indole alkaloid from Tabernanthe iboga, may reduce withdrawal symptoms, craving, and relapse in substance use disorders. A literature review of publications from PubMed, Scopus, Medline, Google Scholar, and SciELO shows ibogaine acts via multiple systems: glutamatergic, opioid, serotonergic, and nicotinic, with possible effects on neuroplasticity and reward circuits. Observational clinical studies indicate reductions in withdrawal and craving, and recent research describes improved psychiatric and cognitive outcomes in controlled settings. However, safety remains a major limitation, particularly the risk of corrected QT interval prolongation, ventricular arrhythmias, and serious cardiac events. The therapeutic potential is relevant but depends on randomized controlled trials, rigorous monitoring, clear regulatory criteria, and hospital protocols to reduce patient risks.
Frontiers in Pharmacology • June 3, 2026 • Burton J. Tabaac, Robin L. Carhart-Harris, Teresa Yung
Three individuals with persistent symptoms after traumatic brain injury or hypoxic-ischemic brain injury completed a six-week protocol combining a participant-directed iboga-containing microdosing regimen (using whole root bark biomass with about 3.845% ibogaine content, yielding an estimated 3.8–38.5 mg/day ibogaine equivalent) with weekly Accelerated Experiential Dynamic Psychotherapy and supportive nutraceuticals. All three showed progressive neurological recovery; two reported complete symptom remission at long-term follow-up. Participants discontinued all prescription medications and reported resolution of headaches, brain fog, fatigue, irritability, and mood swings, with a return to regular activities and renewed enthusiasm. The authors note that the findings do not establish causality or iboga-specific efficacy due to the multimodal intervention and methodological limitations.
Journal of Psychoactive Drugs • May 22, 2026 • Jamie Walker, Daryle Deering, Bruno Hamish Unger
Ten opioid-dependent people in New Zealand who used ibogaine for detoxification described rapid withdrawal relief, improved mood, reduced anxiety, and periods of sustained abstinence, though some later relapsed. Participants were motivated by desperation to be opioid-free and sought ibogaine because of limited treatment options beyond opioid substitution therapy. They emphasized the importance of safety practices, medical screening, and post-treatment psychosocial support for positive outcomes. The study identified seven themes including motivations, treatment effects on depression and anxiety, and spiritual effects. Ibogaine is legally available by prescription in New Zealand, providing a unique context for understanding user experiences.
BMC neuroscience • May 13, 2026 • Alejo Acuña, Federico Billeri, Valentino Totaro et al.
A single dose of ibogaine (40 mg/kg) reinstates juvenile-like experience-dependent plasticity in the adult mouse visual cortex. Adult mice given ibogaine and then four days of monocular deprivation showed reduced visual acuity in the deprived eye and decreased dendritic spine density in the binocular visual cortex, effects not seen in vehicle-treated mice. Ibogaine alone did not alter these measures. The plasticity-enhancing effect was accompanied by reductions in perineuronal nets, parvalbumin-positive interneuron staining, and vesicular GABA transporter-labeled inhibitory puncta. These findings suggest ibogaine can reopen windows of heightened cortical adaptability by reducing structural and inhibitory brakes on plasticity.
Journal of Psychopharmacology • May 12, 2026 • Pravesh Sharma, Jared Kendrick, Jennifer Schram et al.
A review of human studies on ibogaine and its metabolite noribogaine found only three randomized controlled trials. In one pilot study, a single 1800 mg dose of ibogaine reduced cocaine craving versus placebo over up to 24 weeks in 20 adults. Noribogaine doses of 3-60 mg were safe in 36 healthy volunteers. In 27 opioid-dependent patients, noribogaine 60-180 mg caused dose-dependent QTc prolongation with non-significant reductions in withdrawal symptoms. Adverse effects include neurologic, psychiatric, and cardiac events, and fatalities have occurred with comorbidities. Microdosing protocols lack standardized definitions and are supported only by preliminary observational data. The authors conclude that clinical use cannot be recommended without larger, well-controlled trials due to cardiotoxicity and a narrow therapeutic margin.
Nature • May 1, 2019 • Jonathan A Coleman, Dongxue Yang, Zhiyu Zhao et al. • 301 citations
The serotonin transporter (SERT) recycles serotonin into neurons, and its inhibition by drugs like selective serotonin reuptake inhibitors treats depression and anxiety. Using cryo-electron microscopy, the structures of SERT bound to ibogaine—a natural compound with psychoactive and anti-addictive properties—were captured in three conformations: outward-open, occluded, and inward-open. Ibogaine binds to the central site, and the transition from outward-open to inward-open involves movements of specific transmembrane helices and partial unwinding of another, creating a pathway for substrate and ion release into the cytoplasm. These structures reveal the conformational changes underlying neurotransmitter transport and how ibogaine inhibits SERT.
The American journal of drug and alcohol abuse • January 1, 2018 • Thomas Kingsley Brown, Kenneth Alper • 156 citations
Ibogaine, a plant alkaloid, was associated with reduced opioid withdrawal symptoms and drug use in 30 people dependent on heroin or prescription opioids who had not benefited from other treatments. Withdrawal scores dropped from 31 to 14 within about three days. One month after treatment, half of the subjects reported no opioid use in the previous 30 days. Improvements in drug use, legal, and family or social problems were sustained for up to 12 months, though the strongest effect on drug use was at one month. These findings suggest ibogaine may offer a new model for addiction pharmacotherapy.
The American journal of drug and alcohol abuse • January 1, 2018 • Geoffrey E Noller, Chris M Frampton, Berra Yazar-Klosinski • 150 citations
A single ibogaine treatment reduced opioid withdrawal symptoms and led to opioid cessation or sustained reduced use over 12 months in dependent individuals. Among 14 participants (50% female) receiving legal ibogaine treatment in New Zealand, addiction severity scores dropped significantly from baseline to 12-month follow-up for the 8 who completed all interviews. Depression scores also significantly decreased. Opioid withdrawal symptoms fell acutely after treatment for all 14 participants. One patient died during treatment. Legal availability in New Zealand may improve outcomes by allowing treatment providers to collaborate with other health professionals.
Journal of ethnopharmacology • January 4, 2008 • Kenneth R Alper, Howard S Lotsof, Charles D Kaplan • 184 citations
Ibogaine, a naturally occurring psychoactive alkaloid, is used within a global medical subculture to treat substance-related disorders, particularly opioid withdrawal. As of February 2006, an estimated 3,414 individuals had taken ibogaine—a fourfold increase from five years earlier—with 68% doing so for a substance-related disorder and 53% specifically for opioid withdrawal, the most common reason. The subculture lacks clinical and pharmaceutical standards, posing risks. Ethnographic analysis identified four types of ibogaine scenes: medical model, lay provider/treatment guide, activist/self-help, and religious/spiritual. The focus on opioid withdrawal distinguishes ibogaine from other psychedelics and aligns with experimental evidence of a significant pharmacologically mediated effect.
The Journal of biological chemistry • October 5, 2007 • Miriam T Jacobs, Yuan-wei Zhang, Scott D Campbell et al. • 149 citations
Ibogaine, a hallucinogenic alkaloid reported to help treat addiction, inhibits the serotonin transporter (SERT) through a noncompetitive mechanism, reducing the maximum transport rate (Vmax) with little effect on serotonin's binding affinity (Km). It also competitively blocks binding of a cocaine analog to SERT, increasing the apparent dissociation constant (KD) without altering the number of binding sites (Bmax). Ibogaine increases reactivity of cysteine residues in the proposed cytoplasmic permeation pathway of SERT but slows reactivity of cysteines in the extracellular pathway. These findings suggest ibogaine binds to and stabilizes the SERT state from which serotonin dissociates into the cytoplasm, opposite to cocaine's action, which stabilizes the state that binds extracellular serotonin.
Journal of Neuroscience • January 19, 2005 • Dao‐yao He, Nancy N. H. Mcgough, Ajay Ravindranathan et al. • 181 citations
Ibogaine, a natural alkaloid with side effects that prevent clinical use, reduces alcohol consumption in rats. In two-bottle choice and operant self-administration tests, ibogaine decreased ethanol intake and also reduced relapse-like drinking. The effect is mediated by glial cell line-derived neurotrophic factor (GDNF) in the ventral tegmental area (VTA): ibogaine microinjected into the VTA reduced self-administration, systemic ibogaine increased GDNF expression in the midbrain, and in dopaminergic SHSY5Y cells ibogaine activated the GDNF pathway (phosphorylation of Ret and ERK1). Intra-VTA GDNF mimicked ibogaine's effect, while anti-GDNF antibodies blocked it. GDNF in the VTA therefore mediates ibogaine's action on ethanol consumption, suggesting GDNF as a target for alcoholism medications that could avoid ibogaine's side effects.
Annals of the New York Academy of Sciences • September 1, 2000 • D C Mash, C A Kovera, J Pablo et al. • 146 citations
Ibogaine, an indole alkaloid from the Tabernanthe Iboga shrub, has been used in low doses by indigenous peoples to combat fatigue, hunger, and thirst, and in higher doses as a religious sacrament. Anecdotal reports from addict self-help groups claim a single dose eliminates opiate withdrawal symptoms and reduces drug craving for extended periods. The compound is rapidly metabolized via CYP2D6 into noribogaine, which may underlie its prolonged effects. In an inpatient detoxification setting, ibogaine significantly decreased craving for cocaine and heroin and reduced self-reported depressive symptoms, with benefits persisting 30 days after discharge. The findings suggest noribogaine's central nervous system activity may explain the lasting aftereffects on craving and mood.
The American journal on addictions • January 1, 1999 • K R Alper, H S Lotsof, G M Frenken et al. • 201 citations
In a review of 33 cases of ibogaine treatment for opioid detoxification in non-medical settings, 25 patients showed complete resolution of opioid withdrawal signs and cessation of drug-seeking behavior within 24 hours, sustained over 72 hours. Other outcomes included drug-seeking without withdrawal (4 patients), abstinence with attenuated withdrawal (2 patients), drug-seeking with continued withdrawal (1 patient), and one fatality possibly from surreptitious heroin use. The average daily heroin use was 0.64 grams, primarily intravenously. The findings suggest the need for systematic clinical research to confirm ibogaine's potential for rapidly alleviating severe opioid withdrawal.
Journal of Neuroscience • November 15, 1997 • Elizabeth O’hearn, Mark E. Molliver • 158 citations
Ibogaine, an alkaloid causing hallucinations, tremor, and ataxia, leads to degeneration of Purkinje cells in the rat cerebellum in narrow parasagittal bands, accompanied by activated glial cells. Harmaline, a related alkaloid that excites inferior olivary neurons, produces the same pattern. The authors hypothesized that ibogaine excites inferior olive neurons, causing sustained glutamate release at climbing fiber synapses, mediating excitotoxic Purkinje cell death. Pharmacologically ablating the inferior olive in rats with 3-acetylpyridine before ibogaine administration almost completely prevented Purkinje cell degeneration and glial activation. This demonstrates ibogaine is not directly toxic but depends on an intact olivocerebellar projection. The unique circuitry of this projection provides high synaptic security, making Purkinje cells vulnerable to excitotoxic injury.
Life sciences • January 1, 1995 • R H Mach, C R Smith, S R Childers • 145 citations
Ibogaine, an alkaloid that may reduce cravings for addictive drugs, binds more strongly to sigma-2 receptors (Ki = 90.4 and 250 nM) than to sigma-1 receptors (Ki = 9310 nM). This suggests sigma-2 receptors could be its primary target in the central nervous system, and its low affinity for sigma-1 receptors makes it a promising starting point for developing drugs selective for sigma-2 receptors.
Brain research • September 19, 1994 • S D Glick, M E Kuehne, J Raucci et al. • 189 citations
Several iboga alkaloids and the related harmala alkaloid harmaline reduce morphine and cocaine self-administration in rats in a dose-dependent manner (2.5-80 mg/kg) during the hour after treatment. Some alkaloids, including ibogaine, tabernanthine, desethylcoronaridine, and the R-isomers of coronaridine and ibogamine, also decrease intake the following day. In some rats, a single injection or two to three weekly injections produce persistent decreases lasting several days, with R-ibogamine showing the most consistent long-term effects. The study also assessed the tremor-inducing and neurotoxic potential of these compounds and their effects on dopamine levels in brain reward regions.
Journal of substance abuse treatment • January 1, 1994 • S G Sheppard • 162 citations
A single high dose of ibogaine, a naturally occurring psychotropic alkaloid, eliminated opiate withdrawal symptoms in seven addicted individuals. At doses of 700–1800 mg, none showed significant withdrawal after the 24–38-hour psychoactive period. Of the six who took 1000 mg or more, two relapsed after weeks, one returned to intermittent heroin use, and three remained drug-free for at least 14 weeks. The one who took 700 mg resumed abuse after 2 days. Ibogaine may help treat substance abuse and inspire future medications.
European journal of pharmacology • September 14, 1993 • S L Cappendijk, M R Dzoljic • 176 citations
A single injection of ibogaine (40 mg/kg) in rats significantly reduced cocaine self-administration for more than 48 hours. Because ibogaine's half-life is short, one or more of its active metabolites may be responsible. Repeated ibogaine doses over three consecutive days also decreased cocaine intake, and the strongest effect came from weekly injections for three weeks. These findings suggest ibogaine or its metabolites can produce a long-lasting interruption of cocaine dependence, consistent with uncontrolled clinical observations.
Neuroscience • July 1, 1993 • E O'hearn, M E Molliver • 220 citations
The psychoactive compounds ibogaine and harmaline, both beta-carboline derivatives known to cause hallucinations and tremor, can damage specific neurons in the cerebellum. In rats, a single treatment with either drug led to the degeneration of Purkinje cells in narrow, striped regions of the cerebellar vermis, as shown by loss of specific neuronal proteins and silver staining of dying cells. The damage was confined to parasagittal stripes, matching the organization of climbing fiber inputs from the inferior olive. The authors conclude that both drugs have selective neurotoxic effects on Purkinje cells and suggest that sustained activation of inferior olivary neurons may cause excitotoxic degeneration via release of an excitatory amino acid from climbing fiber terminals.